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Abstract 
Optimizing the therapeutic strategies based
on the results of randomized studies compar-
ing different regimens led to a better prognosis
of nearly all pediatric malignancies during the
past four decades. Fever and neutropenia (FN)
is a common complication in patients undergo-
ing chemotherapy to treat cancer. There is no
consensus on when standard therapy can be
safely reduced; this lack of consensus leads to
important  variations  in  management  of  FN
between  different  institutions,  usually  con-
ducted according to local attitudes. To address
this issue, the Infection working group of the
Italian  association  for  pediatric  hematology
oncology  (AIEOP)  organized  a  consensus
meeting.  This  paper  reports  the  agreement
derived from this meeting.  
Introduction
Optimizing the therapeutic strategies based
on the results of randomized studies compar-
ing different regimens led to a better prognosis
of nearly all pediatric malignancies during the
past four decades. While morbidity and mortal-
ity of the malignancy itself have been reduced,
infections, with or without severe neutrope-
nia,  remain  the  most  frequent  potentially
lethal complications of therapy.1
Fever and neutropenia (FN) is a common
complication  in  patients  undergoing
chemotherapy  to  treat  cancer.  For  decades
empiric  treatment  with  intravenous  (IV)
broad-spectrum  antibiotics  in  an  in-patient
setting has been the mainstay of therapy for
FN in pediatric patients.2 With the advent of
aggressive management of FN, the outcome of
episodes  in  children  improved  dramatically.
Mortality fell from 30-40% in the 1970s to 1% in
the late 1990s.3 To achieve those results, the
standard of supportive care became very pro-
tective; yet, this probably led to the overtreat-
ment  of  a  substantial  group  of  patients.  All
these measures have a potential to induce side
effects, such as promoting microbial resistanc-
es  in  the  case  of  antibiotics,  reducing  the
patient’s quality of life, and further increasing
the treatment costs.1,4On the other hand, there
is no consensus on when standard therapy can
be safely reduced; this lack of consensus leads
to important variations in management of FN
between  different  institutions,  usually  con-
ducted according to local attitudes.
To address this issue, the Infection working
group of the Italian Association for Pediatric
Hematology  Oncology  (AIEOP)  organized  a
consensus  meeting.  This  paper  reports  the
agreement derived from this meeting.  
Patient stratification 
Large-scale  adult  studies  have  produced
detailed scoring systems to identify episodes of
low-risk febrile neutropenia within the first 24
h of initial presentation.5,6 The ultimate goal of
risk stratiﬁcation is to identify patients at low
risk in order to offer them less aggressive ther-
apeutic approaches, such as shortened antimi-
crobial  treatment,  early  hospital  discharge,
oral  antibiotic  therapy,  and  outpatient  man-
agement. 
In  children  with  FN  however,  presenting
characteristics and outcome differ significant-
ly from those found in adult patients.7 Models
of risk prediction for FN-related morbidity and
mortality and risk-based stratification of care
including outpatient and oral antibiotics have
been  suggested  in  pediatic  patients.8-12 The
generalization of these study results, however,
is limited due to a variety of inconsistencies,
including i) different definitions of outcome
criteria; ii) missing data sets in retrospective
studies  and,  and  most  importantly;  iii)  the
high  variability  of  patient  cohorts  including
ethnic diversities, sample size, and center-to-
center variations (single-center vs. multi-cen-
ter  trials).13 However,  only  a  selection  of
parameters have proven to have value in the
various prospective intervention studies: good
clinical condition, no comorbidity needing hos-
pitalization,  indication  or  evidence  of  bone
marrow recovery/activity, being afebrile, con-
trol of local infection, negative BC, low inﬂam-
mation  laboratory  parameters  (IL-8,  CRP),
chemotherapy ≥7 days previous, neutropenia
expected to prolong <10 days, stable disease or
remission.14 In this setting non-medical barri-
ers  (e.g  language  barriers,  reliable  family/
caretakers, the possibility of being able to con-
tact and come to the hospital within a short
period  of  time),  to  outpatient  treatment  of
Fever  and  Neutropenia  in  Children  With
Cancer11,14 should  be  carefully  considered.
Finally, even among those patients who may be
considered to do well enough to be eligible for
an outpatient care, in many cases either the
family or the treating physician did not ﬁnd the
prospect  of  outpatient  care  appealing
enough.9,15 In fact, according to data from Sung
et al.,16 only 53% of parents would choose out-
patient  oral  antibiotic  management  for  low-
risk febrile neutropenia.
Which treatment approach for
patients considered at lower risk?
However, despite the lack of a single, vali-
dated  risk-prediction  system  for  paediatric
from febrile neutropenia, many studies have
compared differing approaches to treatment in
febrile neutropenia episodes identified as low
risk  by  local  criteria.  Useful  approaches  to
reduced-intensity  treatment  include  i)  early
discharge  on  ambulatory  intravenous  treat-
ment; ii) step-down treatment (starting with
intravenous  antibiotics  and  moving  to  oral
treatment after a period of 8-48 h); iii) oral
antibiotics  from  the  outset  of  the  episode,
given in the hospital or as an outpatient. 
Heterogeneity of the therapeutic
approaches 
An  international  consensus  on  when  and
how to assess the risk of which kind of adverse
events in pediatric FN is still lacking14,17 and
this induced major variations among the poli-
cies adopted among different centers partici-
pating to the AIEOP, as well as in other coun-
tries and cooperative groups. In this context
Boracina et al. undertook a cross sectional sur-
vey of all Canadian tertiary pediatric centers
in  order  to  better  understand  the  Canadian
practices for the management of febrile neu-
tropenic children and to determine the preva-
lence of alternatives to traditional treatment
for  patients  at  low  risk  of  severe  bacterial
infection.18The authors reported that three out
of seventeen Canadian centers carry out exclu-
sively traditional management. The remaining
14 offer modiﬁed treatment for low risk chil-
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dren, mostly they carry out an early discharge
approach; only a few centers implement com-
plete outpatient management. 
The striking variation across the UK in the
treatment of febrile neutropenia has been also
reported from Phillips et al.; they documented
that a child with acute lymphoblastic leukemia
is with chemotherapy at the regional center,
according to the national treatment protocol,
regardless  where  he  lives.19 Yet,  they  report
that  the  policies  adopted  by  the  different
hematology-oncology centers participating in
the United Kingdom Children’s Cancer Study
Group varied very widely, in almost all aspects,
starting  from  the  definitions  of  febrile and
neutropenic, up to the use of risk stratification
and duration of antibiotic therapy.20
Comparably,  the  results  of  a  survey  per-
formed in 2007 on eleven italian centers, mem-
bers  of  the  AIEOP  network,  showed  a  large
variability of treatment strategies adopted in
episodes of febrile neutropenia.
How to select the therapeutic strategy?
After defining the best criteria to define the
risk of each child to develop sepsis, the next
step is how to harmonize the treatments and
what therapeutic method to use: i) Home treat-
ment or day-hospital every day? ii) Treatment
with  antibiotics  orally  or  parenterally?  iii)
Which molecules to use? iv) How long should
treatment  last?  The  most  convenient  choice
would  be  an  oral  product,  since  it  improves
compliance and, in a setting of low risk for sep-
sis, allows remote monitoring of the conditions
of the child who may remain at home until the
end of treatment. The timing and type of the
controls during the treatment, depend on the
clinical and logistic situation. However, in the
presence of features such as incompletely low
risk,  or  bad    compliance  to  treatment,  also
according to the distance of the child’s domi-
cile from the caregiver site, single daily dose of
parenteral antibiotics may be considered. 
In the case of an oral therapy, third genera-
tion  cephalosporin  or  amoxicillin/clavulanate
seem to be the best choice; both drugs have a
good spectrum and confortable formulations. 
If parenteral drugs appear to be preferred,
ceftriaxone might to be the first choice. The
possibility of a single daily parenteral adminis-
tration and the good spectrum are his charac-
teristics. Yet, a good knowledge of the local
epidemiology of bacterial isolates will be very
helpful in order to select and then to update
the empiric antibiotic therapy.21 In particular
situations,  quinolones  might  represent  the
best choice, especially if the child experiences
multiple infections or gram negative bacteria
are  prevalent.  We  have  to  consider  that
ciprofloxacin and levofloxacin, the more used
quinolones, have a different spectrum and a
different use.
In conclusion, many studies are published
regarding  the  home-patient  treatment,  but
they are not homogeneus in selection criteria,
sample size and used drugs. Thus, they do not
allow a conclusive comparison. In this docu-
ment, the panel of expert of the Infection work-
ing group of the Italian association for pedi-
atric hematology oncology (AIEOP) summarize
the consensus achieved in the meeting. Given
the  obvious  difficulties  in  organizing  a
prospective study at this stage, the panel sug-
gest to address these issues within the AIEOP
network by defining a pediatric score for defi-
nition  of  risk  assessment;  furthermore,  the
group expresses its interest in defining a com-
mon set of drugs to be tested in a prospective
data recruitment. This might provide the basis
for definition of a uniform approach to outpa-
tient treatment.
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